Milliman
Medicare Drug Price Negotiations Reshape PACE Pharmacy Economics
The analysis explains how Medicare's maximum fair price (MFP) negotiations, now expanding to Part B drugs in 2028, are altering pharmacy cost and revenue dynamics for PACE organizations, which serve frail dual-eligible seniors often overlapping with Medicaid managed care populations. It cautions that lower negotiated drug prices do not automatically improve margins because of complex interactions with rebates, 340B pricing, and CMS's Part D reconciliation process, urging PACE organizations to closely monitor utilization and net costs as more drugs become subject to MFP.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.